[Lipids-Diagnosis and therapy in diabetes mellitus (Update 2023)].
Lipide: Diagnostik und Therapie bei Diabetes mellitus (Update 2023).
Diabetes mellitus
Hyperlipidemia
Statins
Journal
Wiener klinische Wochenschrift
ISSN: 1613-7671
Titre abrégé: Wien Klin Wochenschr
Pays: Austria
ID NLM: 21620870R
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
22
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Hyper- and dyslipidemia contribute to cardiovascular morbidity and mortality in diabetic patients. Pharmacological therapy to lower LDL cholesterol has convincingly shown to reduce cardiovascular risk in diabetic patients. The present article represents the recommendations of the Austrian Diabetes Association for the use of lipid-lowering drugs in diabetic patients according to current scientific evidence. Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass eine medikamentöse Therapie mit Statinen, Ezetimibe und PCSK9 Hemmern das kardiovaskuläre Risiko von Patienten mit Diabetes senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der Österreichischen Diabetes Gesellschaft zum Einsatz lipidsenkender Medikamente dar.
Autres résumés
Type: Publisher
(ger)
Hyper- und Dyslipidämie tragen zur kardiovaskulären Morbidität und Mortalität diabetischer Patienten bei. Überzeugende Daten zeigen, dass eine medikamentöse Therapie mit Statinen, Ezetimibe und PCSK9 Hemmern das kardiovaskuläre Risiko von Patienten mit Diabetes senken kann. Der vorliegende Artikel stellt die Behandlungsvorschläge der Österreichischen Diabetes Gesellschaft zum Einsatz lipidsenkender Medikamente dar.
Identifiants
pubmed: 37101037
doi: 10.1007/s00508-023-02166-8
pii: 10.1007/s00508-023-02166-8
pmc: PMC10133339
doi:
Substances chimiques
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Hypolipidemic Agents
0
Cholesterol, LDL
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
157-160Informations de copyright
© 2023. The Author(s).
Références
Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–337.
doi: 10.1093/eurheartj/ehab484
pubmed: 34458905
The Task Force for the management of dyslipidaemias. 2019 ESC/EAS guidelines fort he management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.
doi: 10.1093/eurheartj/ehz455
Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24:91–120.
doi: 10.4158/CS-2017-0153
pubmed: 29368965
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 trials of statins. Lancet. 2005;366:1267–78.
doi: 10.1016/S0140-6736(05)67394-1
pubmed: 16214597
Cholesterol Treatment Trialists Collaborators.. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–25.
doi: 10.1016/S0140-6736(08)60104-X
Cholesterol Treatment Trialists Collaborators.. The effect of lowering LDL cholesterol with statin therapy in people at low risk of vascular diesease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.
doi: 10.1016/S0140-6736(12)60367-5
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapie after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
doi: 10.1056/NEJMoa1410489
pubmed: 26039521
Sabatine MA, Giugliano RP, Keech AC, Honarpour N, Wiviott ST, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
doi: 10.1056/NEJMoa1615664
pubmed: 28304224
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018; https://doi.org/10.1056/nejmoa1801174 .
doi: 10.1056/nejmoa1801174
pubmed: 30575484
pmcid: 6447029
Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410–8.
doi: 10.1056/NEJM199908053410604
pubmed: 10438259
Keech A, Simmes RJ, Barter B, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type‑2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61.
doi: 10.1016/S0140-6736(05)67667-2
pubmed: 16310551
The ACCORD Study Group.. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.
doi: 10.1056/NEJMoa1001282
pmcid: 2879499
Bhatt DL, Steg G, Miller M, Brinton EL, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
doi: 10.1056/NEJMoa1812792
pubmed: 30415628